Previous 10 | Next 10 |
This article is the first in a series about screens designed by famous investors. For an overview of the subject, see my previous article, Can Screening for Stocks Still Generate Alpha? Benjamin Graham, who has often been called the father of value investing, published The Intelligent I...
AC Immune (NASDAQ: ACIU ) +76% on advancement of Alzheimer's vaccine study. More news on: AC Immune SA, Future FinTech Group Inc., Boxlight Corporation, Stocks on the move, , Read more ...
Gainers: Equillium (NASDAQ: EQ ) +220% . More news on: Equillium, Inc., electroCore, Inc., WiMi Hologram Cloud Inc., Stocks on the move, , Read more ...
Osmotica Receives FDA Approval for Droopy Eyelid Treatment Osmotica Pharmaceuticals Plc ( OSMT ) reported that the FDA has given its approval for the company’s novel treatment for acquired blepharoptosis, or ptosis. Upneeq is now the only FDA-approved medical treatment for acquire...
NextCure (NASDAQ: NXTC ) slips 6% premarket after providing an interim update on the Phase 2 portion of its NC318 monotherapy phase 1/2 trial. More news on: NextCure, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BELTSVILLE, Md., July 13, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an interim update ...
NextCure (NASDAQ: NXTC ) initiates Phase 1/2 trial for NC410, an immunomedicine developed to block immune suppression mediated by an immune modulator called LAIR-1. More news on: NextCure, Inc., Healthcare stocks news, Read more ...
BELTSVILLE, Md., July 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of...
BELTSVILLE, Md., May 29, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentatio...
NextCure (NASDAQ: NXTC ): Q1 GAAP EPS of $0.33 beats by $0.77 . More news on: NextCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...